CoChat

Prospective Enterprise-Level Molecular Genotyping of a Cohort of Cancer Patients

Open access
MacConaill, Laura E., Garcia, Elizabeth, Shivdasani, Priyanka, Ducar, Matthew, Adusumilli, Ravali, Breneiser, Marc, Byrne, Mark, Chung, Lawrence, Conneely, Jodie, Crosby, Lauren, Garraway, Levi A., Gong, Xin, Hahn, William C., Hatton, Charlie, Kantoff, Philip W., Kluk, Michael, Kuo, Frank, Jia, Yonghui, Joshi, Ruchi, Longtine, Janina, Manning, Allison, Palescandolo, Emanuele, Sharaf, Nematullah, Sholl, Lynette, van Hummelen, Paul, Wade, Jacqueline, Wollinson, Bruce M., Zepf, Dimity, Rollins, Barrett J., Lindeman, Neal I. · 2014 · The Journal of Molecular Diagnostics
Cited by 86

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

Ongoing cancer genome characterization studies continue to elucidate the spectrum of genomic abnormalities that drive many cancers, and in the clinical arena assessment of the driver genetic alterations in patients is playing an increasingly important diagnostic and/or prognostic role for many cancer types. However, the landscape of genomic abnormalities is still unknown for less common cancers, and the influence of specific genotypes on clinical behavior is often still unclear. To address some of these deficiencies, we developed Profile, a prospective cohort study to obtain genomic information on all patients at a large tertiary care medical center for cancer-related care. We enrolled patients with any cancer diagnosis, and, for each patient (unselected for cancer site or type) we applied mass spectrometric genotyping (OncoMap) of 471 common recurrent mutations in 41 cancer-related genes. We report the results of the first 5000 patients, of which 26% exhibited potentially actionable somatic mutations. These observations indicate the utility of genotyping in advancing the field of precision oncology.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jmoldx.2014.06.004

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Cited by

See all 86

Metadata

Authors
MacConaill, L. E., Garcia, E., Shivdasani, P., Ducar, M., Adusumilli, R., Breneiser, M., Byrne, M., Chung, L., Conneely, J., Crosby, L., Garraway, L. A., Gong, X., Hahn, W. C., Hatton, C., Kantoff, P. W., Kluk, M., Kuo, F., Jia, Y., Joshi, R., Longtine, J., Manning, A., Palescandolo, E., Sharaf, N., Sholl, L., van Hummelen, P., Wade, J., Wollinson, B. M., Zepf, D., Rollins, B. J., & Lindeman, N. I.
Venue
The Journal of Molecular Diagnostics
Publisher
Elsevier BV
Published
2014-11
Volume
16
Issue
6
Pages
660-672
ISSN
1525-1578 (ISSN-L)
OpenAlex
W2082110197
Cited by
86
References
12
FWCI
3.89
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Prospective Enterprise-Level Molecular Genotyping of a Cohort of Cancer Patients. https://app.cochat.ai/papers/10.1016/j.jmoldx.2014.06.004
The paper
MacConaill, L. E., Garcia, E., Shivdasani, P., Ducar, M., Adusumilli, R., Breneiser, M., Byrne, M., Chung, L., Conneely, J., Crosby, L., Garraway, L. A., Gong, X., Hahn, W. C., Hatton, C., Kantoff, P. W., Kluk, M., Kuo, F., Jia, Y., Joshi, R., . . . Lindeman, N. I. (2014). Prospective Enterprise-Level Molecular Genotyping of a Cohort of Cancer Patients. The Journal of Molecular Diagnostics. https://doi.org/10.1016/j.jmoldx.2014.06.004

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.